Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 31.17% is 94% above its 5-year average of 16.06%, near the high end of its 5-year range (3.15%–39.76%).
As of the fiscal period ended Tuesday, June 30, 2026. 15.43% below its 12-month average of 36.86%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 31.17%.
DEBT TO ASSETS RATIO
31.17%
DEBT TO ASSETS RATIO AVG TTM
36.86%
DEBT TO ASSETS RATIO AVG 3Y
22.68%
DEBT TO ASSETS RATIO AVG 5Y
16.06%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-15.43%
CURRENT VS 3Y AVG
+37.42%
CURRENT VS 5Y AVG
+94.11%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+34532.49%
vs the sector median at left
SOPHiA GENETICS S.A.
Market Cap
$619.15M
Debt to Assets Ratio
31.17%
TTM Avg
36.86%
3Y Avg
22.68%
5Y Avg
16.06%
Market Cap
$632.16M
Debt to Assets Ratio
0.45%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$634.30M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$638.20M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$597.55M
Debt to Assets Ratio
1.39%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$596.01M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$584.48M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SOPHiA GENETICS S.A. (SOPH) | $619.15M | 31.17% | 36.86% | 22.68% | 16.06% |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | 0.01% | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $630.63M | 0.07% | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | 0.45% | N/A | N/A | N/A |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 0.00% | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | 0.05% | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 1.39% | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $596.01M | 0.00% | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.48M | 0.01% | N/A | N/A | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $583.31M | 0.18% | N/A | N/A | N/A |
Debt/Assets
31.2%
Debt/Equity
0.74
Current Ratio
2.69
Interest Coverage
-15.6x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 31.17% |
| 2026-03-31 | 39.76% |
| 2025-12-31 | 38.66% |
| 2025-09-30 | 38.77% |
| 2025-06-30 | 35.93% |
| 2025-03-31 | 20.54% |
| 2024-12-31 | 19.34% |
| 2024-09-30 | 17.83% |
| 2024-06-30 | 16.60% |
| 2024-03-31 | 9.68% |
| 2023-12-31 | 9.02% |
| 2023-09-30 | 8.68% |
| 2023-06-30 | 8.88% |
| 2023-03-31 | 7.65% |
| 2022-12-31 | 6.87% |
| 2022-09-30 | 6.48% |
| 2022-06-30 | 6.05% |
| 2022-03-31 | 4.21% |
| 2021-12-31 | 4.08% |
| 2021-09-30 | 3.87% |
| 2021-06-30 | 3.15% |
| 2021-03-31 | 4.56% |
| 2020-12-31 | 5.49% |
